Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk.
Wu
X
X
Department of Epidemiology, University of Texas M. D. Anderson Cancer Center, Houston, USA.
Yu
H
H
Amos
C I
CI
Hong
W K
WK
Spitz
M R
MR
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D001580:Benzopyrenes; D001761:Bleomycin / Q000494:pharmacology; D016022:Case-Control Studies; D002478:Cells, Cultured; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis; D007335:Insulin-Like Growth Factor II / Q000096:biosynthesis; D008175:Lung Neoplasms / Q000378:metabolism*; D009153:Mutagens; D016017:Odds Ratio; D012307:Risk Factors; D013002:Somatomedins / Q000096:biosynthesis*
D000903:Antibiotics, Antineoplastic; D001580:Benzopyrenes; D018972:Insulin-Like Growth Factor Binding Protein 3; D009153:Mutagens; D013002:Somatomedins; D001761:Bleomycin; C072019:benzo(a)pyrene diolepoxide I; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II